Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (90)

2024

  1. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

2023

  1. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX-FP in the PROLONG-9FP clinical trial program

    European Journal of Haematology, Vol. 111, Núm. 2, pp. 293-299

  2. Expert opinion paper on the treatment of hemophilia a with emicizumab

    Hematology (Amsterdam, Netherlands), Vol. 28, Núm. 1, pp. 2166334

  3. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

    Journal of Thrombosis and Haemostasis

  4. Treatment of high-risk bleeding with susoctocog alfa in a patient with acquired haemophilia A and a nosocomial severe acute respiratory syndrome coronavirus 2 infection

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 3, pp. 177-179

  5. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. Challenging treatment for refractory acquired haemophilia A complicated with severe severe acute respiratory coronavirus 2 infection

    Blood Coagulation and Fibrinolysis, Vol. 33, Núm. 6, pp. 342-347

  3. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 11

  4. IX international curse of continuing formation in haemophilia and other congenital coagulopathies. The role of the Laboratory in coagulation disorders. Diagnosis of von Willebrand disease

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, Vol. 33, pp. S12-S14

  5. Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1369-1378

  6. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

    Blood Advances, Vol. 6, Núm. 17, pp. 5171-5183

  7. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2021

  1. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Español de Trasplante Hematopoyético (GETH)

    Transfusion and Apheresis Science, Vol. 60, Núm. 2

  2. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  3. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  4. Expanding the genetic spectrum of TUBB1-related thrombocytopenia

    Blood Advances, Vol. 5, Núm. 24, pp. 5453-5467

  5. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  6. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

  7. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5